[go: up one dir, main page]

WO2009030092A1 - Milieu de culture et procédé destinés à une culture in vitro de cellules souches mésenchymateuses primaires adultes humaines à grande échelle, cellules souches mésenchymateuses primaires obtenues à l'aide de ce procédé, utilisations correspondantes - Google Patents

Milieu de culture et procédé destinés à une culture in vitro de cellules souches mésenchymateuses primaires adultes humaines à grande échelle, cellules souches mésenchymateuses primaires obtenues à l'aide de ce procédé, utilisations correspondantes Download PDF

Info

Publication number
WO2009030092A1
WO2009030092A1 PCT/CN2007/070637 CN2007070637W WO2009030092A1 WO 2009030092 A1 WO2009030092 A1 WO 2009030092A1 CN 2007070637 W CN2007070637 W CN 2007070637W WO 2009030092 A1 WO2009030092 A1 WO 2009030092A1
Authority
WO
WIPO (PCT)
Prior art keywords
pmscs
cells
mesenchymal stem
human
final concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2007/070637
Other languages
English (en)
Chinese (zh)
Other versions
WO2009030092A9 (fr
Inventor
Chunhua Zhao
Qin Han
Jing Li
Zhao Sun
Jianli Hu
Yashu Zhu
Shan Lu
Chunjing Bian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Basic Medical Sciences of AMMS
Institute of Basic Medical Sciences of CAMS and PUMC
Original Assignee
Institute of Basic Medical Sciences of AMMS
Institute of Basic Medical Sciences of CAMS and PUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Basic Medical Sciences of AMMS, Institute of Basic Medical Sciences of CAMS and PUMC filed Critical Institute of Basic Medical Sciences of AMMS
Priority to CN2007801003999A priority Critical patent/CN101821383B/zh
Priority to PCT/CN2007/070637 priority patent/WO2009030092A1/fr
Publication of WO2009030092A1 publication Critical patent/WO2009030092A1/fr
Anticipated expiration legal-status Critical
Publication of WO2009030092A9 publication Critical patent/WO2009030092A9/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a method for producing human mesenchymal stem cells (pMSCs, cell markers labeled Flkl, Nanog positive) derived from human adult tissue (bone marrow) in vitro and in large scale production thereof, and a preparation product thereof, and the present application also relates to the use of the cells for inhibiting tumor cells Proliferation application.
  • pMSCs human mesenchymal stem cells
  • Flkl cell markers labeled Flkl, Nanog positive
  • Stem cells are a primitive cell population with self-renewal ability and multilineage differentiation potential in vivo. All tissues and organs of the human body are differentiated from stem cells. Stem cells can be roughly divided into two types, one is embryonic stem cells and the other is adult stem cells. Embryonic stem cells are the most primitive stem cells, which can be infinitely replicated and differentiated into any tissue cells. However, due to the current scientific and technological level and ethical restrictions, it is difficult to apply to practical applications in the short term. Recent studies on adult stem cells have shown good prospects for future life sciences.
  • the general method for culturing and purifying adult stem cells mainly uses magnetic beads to sort mesenchymal stem cells, and is cultured under the condition of conventional oxygen content (20% O 2 ), and the medium used is usually added to the animal source.
  • Serum such as bovine or horse serum.
  • mesenchymal stem cells cultured by conventional methods are difficult to meet the requirements of practical applications in terms of stem cell biological characteristics and stem cell differentiation potential; on the other hand, these conventional methods have many disadvantages, for example, when conventional When a medium containing 100-200 ml/L of animal serum is used, it usually has the following disadvantages: First, the average doubling time of the cultured mesenchymal stem cells is long, and the growth rate is not uniform, and cannot be prepared within a prescribed time. The number of cells required; Secondly, the animal serum used inevitably has risk factors such as xenogeneic immune rejection and animal pathogenic infection. In addition, the commonly used magnetic bead sorting process also has a number of disadvantages. First, the cost of use is relatively high.
  • the magnetic beads currently used for cell separation are more expensive. About 10 8 cells per bone marrow sample (20-30ml) need to be separated. The cost of preparation for a single human pMSCs will increase by at least 4,000 yuan. Secondly, the magnetic bead sorting process has a longer operation time in vitro, which greatly increases the chance of cell contamination and has a great influence on the activity of stem cells. Third, the selection of magnetic beads is either positive or negative. When the separation method is selected, different numbers of cells will be lost; the magnetic beads bound to the cells cannot be completely removed in the subsequent process, and finally can be transplanted into the human body with the stem cells, and the magnetic beads have the possibility of negatively affecting human health. .
  • the average oxygen concentration of the arterial blood is about 12%
  • the average oxygen concentration of the tissue is about 3%
  • the main accumulation site of pMSCs The oxygen concentration of a bone marrow is 1%-7%, and the concentration of oxygen in the embryo body enriched in stem cells is lower. Excessive concentrations of oxygen cause cells to produce large amounts of free radicals, which have a damaging effect.
  • pMSCs Primitive mesenchymal stem cells
  • the prepared pMSCs have various biological functions in vivo and in vitro, including rebuilding blood, regenerating blood vessels, reducing fibrotic damage, inhibiting immune rejection, etc., and can be used for multi-tissue organs such as leukemia, myocardial infarction, progressive liver injury, diabetes, and the like. Therapeutic applications of traumatic diseases. Summary of the invention
  • the present application provides a medium for culturing raw mesenchymal stem cells pMSCs derived from human adult tissues, including cell basal medium and human serum, the final concentration of said human serum being 10-100 ml/L.
  • the culture medium provided herein preferably has a final concentration of human serum of 10-30 ml/L.
  • a more preferred human serum has a final concentration of 20 ml/L.
  • the culture medium described in the present application preferably has human serum as human peripheral or cord blood serum.
  • the medium provided by the present application further comprises human serum albumin, epidermal growth factor EGF and platelet-derived growth factor PDGF, wherein the final concentration of the human serum albumin is 5-20 mg/ml, and the epidermal growth
  • the final concentration of the factor is 1-100 ng/ml
  • the final concentration of the platelet-derived growth factor is 1-100 ng/ml.
  • a preferred final concentration of human serum albumin is 5-10 mg/ml
  • a preferred final concentration of epidermal growth factor is 10-30 ng/ml
  • a preferred final concentration of platelet-derived growth factor is 10-30 ng/ml.
  • More preferred human albumin The final concentration is 10 mg/ml, and the more preferred final concentration of epidermal growth factor is 10 ng/ml, and the more preferred final concentration of platelet-derived growth factor is 10 ng/ml.
  • the medium provided by the present application is used to culture bone marrow-derived primitive mesenchymal stem cells.
  • the present application provides a method of culturing original mesenchymal stem cell pMSCs derived from human adult tissue in vitro, the method comprising the following steps:
  • the primary cell suspension is inoculated at a seeding density of 1 ⁇ 10 6 cells/ml in a plastic petri dish containing the medium; in a volume ratio, at 2% (1-5%, preferably 2%)
  • the method is for culturing primitive mesenchymal stem cells derived from bone marrow.
  • the application provides the original mesenchymal stem cells obtained by the above method. Further, the original mesenchymal stem cells have an immunophenotype of Flkl-positive and express the Nanog gene.
  • the application provides the use of the primordial mesenchymal stem cells for the preparation of a medicament for inhibiting tumor cell proliferation.
  • the application provides a pharmaceutical composition comprising the original mesenchymal stem cells.
  • the present application provides an adult original mesenchymal stem cell culture PEPSC, which has the accession number CGMCC No. 2152, and was deposited with the General Microbiology Center of the China Microbial Culture Collection Management Committee on September 4, 2007, including the original Mesenchymal stem cells.
  • the application provides the adult primordial mesenchymal stem cell culture PEPSC, wherein the primordial mesenchymal stem cells have an immunophenotype of FM positive and a Nanog gene.
  • the application provides the use of the adult primordial mesenchymal stem cell culture PEPSC for the preparation of a medicament for inhibiting tumor cell proliferation.
  • the application provides a pharmaceutical composition comprising the adult original mesenchymal stem cell culture PEPSC.
  • Figure 1 Comparison of phenotypic characteristics of pMSCs cultured under conventional oxygen concentration and hypoxic concentration. A low oxygen concentration pMSCs, B conventional oxygen concentration pMSCs.
  • Figure 2 Comparison of cell cycle assays of pMSCs cultured under conventional oxygen concentration and hypoxic concentration. A low oxygen concentration pMSCs, B conventional oxygen concentration pMSCs.
  • Figure 3-1 Study on the differentiation ability of pMSCs cultured under conventional oxygen concentration and hypoxia concentration I: Two weeks after induction into osteoblasts, Von Kossa staining was used to detect calcium deposition. A low oxygen concentration pMSCs, B conventional oxygen concentration pMSCs.
  • Figure 3-2 Study on the differentiation ability of pMSCs cultured under conventional oxygen concentration and hypoxic concentration ⁇ : After 2 weeks of induction to fat cells, oil red O staining. A low oxygen concentration pMSC, B normal oxygen concentration pMSC.
  • Figure 3-3 Study on the differentiation ability of pMSCs cultured under conventional oxygen concentration and hypoxic concentration III: Induction of differentiation into the endothelium on Matrigel gel After 48 hours, a grid-like tube-like structure was formed. A low oxygen concentration pMSCs, B conventional oxygen concentration pMSCs.
  • Figure 4 Comparison of proliferative capacity of pMSCs cultured under conventional oxygen concentration and hypoxic concentration.
  • Figure 5 Comparison of cell morphology in different media of pMSCs:
  • A morphology of pMSCs in 20 ml/L fetal bovine serum medium
  • B morphology of pMSCs in 20 ml/L peripheral blood serum system
  • C morphology of pMSCs in 20 ml/L cord blood serum medium.
  • Figure 7 Comparison of cell cycle of pMSCs in different media.
  • Figure 8-1 Study on the multi-directional differentiation ability of pMSCs in different media I, (Results of oil red “O” staining after three weeks of induction of adipogenic induction system):
  • A fetal bovine serum medium
  • B peripheral blood serum medium
  • C umbilical cord serum medium
  • Figure 8-2 Study of the multi-directional differentiation ability of pMSCs in different media II, (Von Kossa staining results after three weeks of induction of osteogenic induction system: brown shows calcium matrix deposition): A: fetal bovine serum medium; B: peripheral blood serum medium; C: umbilical cord serum medium,
  • Figure 8-3 Study on the multi-directional differentiation ability of pMSCs in different media III, (immunofluorescence staining results after three weeks of neurogenic induction):
  • A fetal bovine serum medium
  • B peripheral blood serum medium
  • C umbilical cord serum medium
  • Figure 10 RT-PCR detection of human pMSCs expressing Nanog, Dkk-1 results.
  • FIG. 11-1 Tumor cell proliferation assay after co-culture with pMSCs:
  • K562 K562 cells cultured alone; K562+pMSC: K562 co-cultured with pMSCs; MCF7: MCF7 cells cultured alone; MCF7+pMSC: MCF7 co-cultured with pMSCs; HL60:: HL60 cells cultured alone; HL60+pMSC: HL60 Co-culture with pMSCs.
  • Figure 11-2 Detection of proliferation of K562 by the addition of neutralizing antibodies or transwell when K562 is co-cultured with pMSCs:
  • Group 1 K562 cells cultured alone; Group 2: K562 cells co-cultured with pMSCs; Group 3: K562 cells co-cultured with pMSCs, anti-Dkk-1 added to the medium; Group 4: Co-cultured with pMSCs K562 cells, and use transwell to separate the two cells.
  • Figure 11-3 Interference effects of Dkk-1 and Nanog after transfection of RNA interference vectors with pMSCs
  • SiM expression of Nanog in pMSCs transfected with empty vector control
  • SiN expression of Nanog in pMSCs transfected with SiNanog vector
  • SiM expression level of Dkk-1 in pMSCs transfected with empty vector control
  • SiD Table of Dkk-1 in pMSCs transfected with SiDKKl vector Yield
  • SiN expression level of Dkk-1 in pMSCs transfected with SiNanog vector
  • FIG. 11-4 pMSCs after interference with Nanog and Dkk-1 were co-cultured with K562 to detect changes in K562 cell cycle:
  • Group 1 K562 cells cultured alone; Group 2: K562 cells co-cultured with pMSCs transfected with empty vector control; Group 3: K562 cells co-cultured with pMSCs transfected with SiDKKl vector; Group 4: Transfected with SiNanog Vectors of pMSCs co-cultured with K562 cells.
  • Figure ll-5 pMSCs after interference with Nanog and Dkk-1 were co-cultured with K562, and the accumulation of ⁇ -catenin in K562 cells was detected by Western blot.
  • Figure 11-6 pMSCs after interference with Nanog and Dkk-1 were co-cultured with K562, and the gene expression of cell cycle-associated proteins in K562 was detected by quantitative PCR:
  • Quantitative PCR was used to detect P21 expression
  • B Quantitative PCR was used to detect P27 expression
  • C Quantitative PCR was used to detect c-myc expression
  • D Quantitative PCR was used to detect cyclinD2 expression.
  • K562 K562 cells cultured alone; K562+SiM: K562 cells co-cultured with pMSCs transfected with empty vector control; K562+SiD: K562 cells co-cultured with pMSCs transfected with SiDKKl vector; K562+SiN: with K562 cells co-cultured with pMSCs stained with SiNanog vector.
  • the object of the present application is to provide an improved method for the isolation and culture of human adult tissue (bone marrow) derived pMSCs in vitro.
  • the method for isolating and culturing human pMSCs provided by the present application is to obtain a certain amount of bone marrow tissue.
  • the primary seed cells are collected, and the collected cells are seeded in a plastic culture dish and added to a specific cell culture medium.
  • the biggest advantage of this method compared with the traditional stem cell sorting method is that the magnetic bead sorting purification process is abandoned.
  • the magnetic bead sorting process is costly to use.
  • the magnetic beads currently used for cell separation are more expensive. About 10 8 cells per bone marrow sample (20-30ml) need to be separated, and the cost of preparation of single human pMSCs will increase at least. 4,000 yuan; Secondly, the magnetic bead sorting process has a longer operation time in vitro, which greatly increases the chance of cell contamination and has a great influence on stem cell activity. Third, the separation of magnetic beads is performed by positive or negative selection. Different numbers of cells will be lost; the magnetic beads bound to the cells cannot be completely removed in the subsequent process, and finally can be transplanted into the human body with stem cells, and these magnetic beads have the possibility of negatively affecting human health.
  • the method provided by the present application greatly simplifies the cell purification process step, improves the production efficiency, and reduces the production process cost, and the usual stem cell culture method can only be prepared in a small amount, and is only suitable for scientific research, and the proliferation ability and culture of the cell itself. The cost is difficult to meet the requirements of large-scale production preparation.
  • the pMSCs culture preparation method provided by the present application is different from the conventional stem cell culture in that a culture condition of a low concentration of 0 2 is employed in the whole process of preparation and culture of pMSCs.
  • In vitro cell culture is generally carried out at a concentration of 20% O 2 , and the oxygen concentration in the body is significantly lower than this value.
  • the average oxygen concentration of arterial blood is about 12%
  • the average oxygen concentration of tissue is about 3%
  • the main accumulation site of pMSCs The oxygen concentration of a bone marrow is 1%-7%
  • the concentration of oxygen in the embryo body enriched in stem cells is lower.
  • the so-called low oxygen concentration is more in line with the physiological state.
  • pMSCs were cultured under physiological conditions (2% volume concentration of 0 2 ), which is more suitable for growth, proliferation and maintenance of undifferentiated state of pMSCs than conventional oxygen concentration conditions (20% volume concentration of 0 2 ).
  • the hypoxic concentration culture environment used in the present application is provided by a constant temperature three-gas incubator, and has simple operation and good repeatability, and is suitable for large-scale cultivation.
  • the present application provides a new medium that is different from conventional bovine serum medium, which contains human serum.
  • the conventional adult stem cell culture (base) system uses fetal bovine serum culture medium, and the fetal bovine serum added to the system is heterologously derived from the human species, and there is a potential risk of contaminating the exogenous xenogeneic pathogen. Similar to serum one
  • the stem cell culture of the class must be added to the humanization transformation will be the main improvement direction of the future development of stem cell production technology.
  • the present application first invented a human serum medium instead of fetal bovine serum medium, and successfully prepared adult stem cells of the same quality as the original medium under the system (Table 1).
  • the medium provided by the present application also includes human albumin products.
  • the serum in the preferred medium of the present application is derived from human peripheral blood serum/umbilical cord blood serum.
  • Human serum and human serum albumin replace the fetal bovine serum and bovine serum albumin components in the conventional medium formulation, respectively, thereby realizing the humanization of all heterogeneously added components in the culture solution.
  • another significant advantage is: the human umbilical cord blood serum used in the medium comes from the cord blood storage (library) mechanism, and the cord blood serum is a by-product discarded after the cord blood hematopoietic stem cells are collected before the cord blood is stored.
  • cord blood serum contains a large number of cytokines and nutrients, which can be used as a substitute for fetal bovine serum, and the source of cord blood and its collection and processing techniques fully ensure that the serum itself is clean and non-polluting, and its source is very convenient (umbilical cord).
  • the recycling of blood processing wastes ensures the supply of medium supplements during the large-scale preparation of adult stem cells, and also greatly reduces the cost of preparation of adult stem cells (the serum products are expensive and rely on imports).
  • the adult stem cell pMSCs were prepared in vitro using the above human serum medium.
  • the results showed that the quantity and quality of the pMSCs prepared according to the method of the present application reached the quality standard and fully met the requirements for clinical treatment (Fig. 5 - Fig. 9). .
  • the use of this medium avoids the possibility of heterogeneous immune rejection and the risk of unknown virus infection in animal serum, and the clinical application is safer and more reliable.
  • peripheral blood serum and cord blood serum used in the present application are all derived from the process products complying with the GMP requirements, and the human serum albumin is a listed product in conformity with the national drug standard, and the above conditions ensure the process technology using the human serum medium.
  • the primary cells are repeatedly cultured 3-4 times in a dedicated medium to obtain human primordial mesenchymal stem cells which meet the purity requirements.
  • the harvested cells are seeded in a plastic petri dish at a seeding density of 5 ⁇ 10 4 cells/ml;
  • the culture conditions of the culture are 5% C ⁇ 2 , 2% 0 2 , 37 ° C and a saturated humidity incubator.
  • the isolated culture method of the present application is suitable for isolating pMSCs from bone marrow tissues, cells
  • the purification method is applicable to pMSCs of various tissue sources.
  • the separation and culture method is simple, efficient, and low in cost.
  • the cultured pMSCs have CD31-, CD34 ⁇ CD45- and HLA-DR- (negative), and CD29 + , CD44 + , CD105+ and FM + (positive) phenotypes.
  • Human pMSCs prepared by the method of the present invention can express specific cell markers Flkl and Nanogo Flkl are specific cell surface markers for controlling the purity and cell quality of pMSCs in large scale preparation; Nanog is a transcription factor involved in DKK-1 gene.
  • the transcriptional regulation affects the expression of its protein, and regulates the accumulation of ⁇ -catenin in the cell through the Wnt signaling pathway, affecting the ⁇ -catenin nuclear-promoting cells, and inhibiting the proliferation of tumor cells from the G1 phase to the S phase.
  • the expression of Nanocell-derived pMSCs can inhibit the proliferation of tumor cells.
  • the mechanism of inhibition of tumors is through the secretion of the soluble factor DKK-1 molecule, which inhibits tumor cells in the G0/G1 quiescent phase.
  • the pMSCs obtained in the present application can be applied to inhibit tumor cell proliferation.
  • pMSCs were co-cultured with various human hematological tumor cells, and the Nanog gene was expressed by pMSCs to regulate Dkk protein expression, and finally the Wnt signaling pathway was used to significantly inhibit tumor cell proliferation (Fig. 11).
  • Further research on its mechanism of action first using neutralizing antibody technology to prove that pMSCs affect tumor cell proliferation mainly through the secretion of Dkk protein, after using RNAi technology to interfere with the expression of Nanog expression or Dkk secretion of pMSCs, pMSCs on the tumor cell cycle The impact is significantly weakened.
  • pMSCs have the effect of inhibiting the proliferation of tumor cells, but mature stromal cells do not have this effect.
  • This application is the first to express Nanog protein by using pMSCs (current studies suggest that Nanog protein is not expressed except for embryonic stem cell expression)
  • the expression of Dkk protein is specifically regulated, so that the Dkk protein can influence the cycle of tumor cells through the wnt signaling pathway, and finally inhibit the growth and proliferation of tumor cells.
  • the pMSCs obtained by the present application and the method for inhibiting the same are applicable to hematological tumors such as erythroleukemia and promyelocytic leukemia, and provide basic theoretical and clinical research evidence for treating other system tissues such as breast cancer, and are tumors. Treatment offers a new approach.
  • Example 1 In vitro scale-up preparation culture method of human pMSCs
  • the specific cell culture medium used for the large-scale preparation of human pMSCs used in the present application includes cell basal medium, human serum, human serum albumin, epidermal growth factor (EGF) and platelet-derived growth factor (PDGF);
  • the final concentration is 10-100 ml/L
  • the final concentration of the human serum albumin is (5-20 mg/ml)
  • the final concentration of the epidermal growth factor is 1-100 ng/ml
  • the platelet-derived growth factor The final concentration is l-100 ng/ml.
  • the cell basal medium may be any one of DMEM/F 12, MCDB-201, DMEM, MEM, RPMI1640, DMEM, M199, BME, IMEM, or the like, or any combination thereof.
  • type I collagenase was purchased from Sigma; trypsin was purchased from Gibco; DMEM/F12 (ie DF12), M199, MEM, RPMI1640, BME, IMEM and DMEM were purchased from GIBCO; MCDB-201 was purchased from Sigma; EGF was purchased from Gibco; PDGF, VEGF and bFGF were purchased from Sigma; hydrocortisone was purchased from Sigma; FCS and horse serum (HS) were purchased from Hyclone; human albumin was purchased from Harbin Shiheng Bioengineering Company; Human prothrombin is a gift from Shanghai Lai Shi Blood Products Co., Ltd.; Human umbilical cord blood serum is donated by Beijing Cord Blood Bank; Human peripheral blood serum is self-made (natural coagulation is obtained, which is a classic textbook method). 2. In vitro large-scale preparation and culture method of human pMSCs
  • Human adult tissue mononuclear cells were obtained according to the methods disclosed in the prior art, and human adult tissue mononuclear cells were suspended in a medium containing 2% human serum to obtain a human adult tissue primary cell suspension.
  • 2.1 15 ml of a mononuclear cell suspension of the above density (1 x 10 6 /ml) was inoculated into a 175 flask of the cell culture medium of the present application.
  • the conditions of the three-gas culture incubator were previously set to 1-5% 0 2 , preferably 2% 0 2 , 5% C0 2 , 37 ° C, and pre-equilibrated for 3-5 hours, and then the cells were placed in an incubator.
  • the cultured expanded pMSCs were digested with 0.25% trypsin 10 ml for 2 minutes, then 0.2 ml of human serum was added to terminate the digestion, and the mixture was centrifuged at 100 rpm for 5 minutes.
  • the cells were cryopreserved in liquid nitrogen after being cooled by process control.
  • the cryopreserved cell culture is named adult original mesenchymal stem cell culture
  • PEPSC deposited with the General Microbiology Center of the China Microbial Culture Collection Management Committee on September 4, 2007, has a deposit number of CGMCC No. 2152.
  • the pMSCs obtained by the culture method described in the present application were compared with the pMSCs obtained under the conventional oxygen concentration conditions (the other culture conditions except the oxygen concentration were the same as in the present application), and the following biological characteristics were compared and measured.
  • the spindle cell phenotype obtained after culture was detected by direct immunofluorescence, and the cells were labeled with anti-human CD29, CD44, CD105, Flk-1, labeled with fluorescein isothiocyanate (FITC) or phycoerythrin (PE).
  • CD31, CD34, CD45 and HLA-DR antibodies (all of which were purchased from BD) were labeled for flow detection, and the flow cytometry was BD FACScan (Becton Dickinson)
  • the cell cycle was measured by flow cytometry.
  • the cells were fixed with 80% cold ethanol at 4 ° C for 1 h, washed twice with PBS, resuspended in 0.5 ml PBS, added with RnaseA (100 g/ml), and incubated at 37 °C for 30 minutes. Stained with propidium iodide (Sigma, 5 ⁇ g/ml) before the measurement. Cell cycle was analyzed with ModiFit software (Becton Dickinson).
  • the phenotypic results showed that the pMSCs cultured in the conventional oxygen concentration and the low oxygen concentration had no obvious region, and the positive rate of CD29, CD44, CD105 and Flk-1 in the spindle cells obtained from the expanded culture was over 95%, CD31.
  • the positive rates of CD34, CD45 and MHC class II molecules are below 5% (Fig. 1).
  • the results of cell cycle assay showed that most of the spindle cells obtained in the expanded culture were in G0/G1 phase, while the proportion of cells in G2-M phase and S phase was very low (Fig. 2).
  • the pMSCs cultured in the 10th generation conventional oxygen concentration and low oxygen concentration were induced to differentiate into osteoblasts, fat and endothelium by conventional methods. It was found that there was no significant difference in the differentiation ability of the two pMSCs (Fig. 3-1, 3-2). , 3-3). 3. Proliferation ability of pMSCs
  • the 10th generation of pMSCs cultured at the conventional oxygen concentration and the low oxygen concentration were taken, and the cells were seeded in a 24-well plate at 5 ⁇ 10 3 cells/well, then 3 wells were digested every 24 hours, and the cells were collected and 0.4% of the fetuses were used. Panlan counts live cells and then plots the growth curve. The results showed that the proliferation of pMSCs cultured at low oxygen concentration was faster, and the doubling time was about 26 hours. The doubling time of conventional oxygen concentration pMSCs was about 30 hours, and the difference was statistically significant (t test, p ⁇ 0.05) (Fig. 4).
  • Example 3 Study comparison Results of new medium and conventional medium provided by the present application on human pMSCs cell culture
  • the specific cell culture medium used for the large-scale preparation of human pMSCs including cell basal medium, human serum, human serum albumin, epidermal growth factor (EGF), and platelet-derived growth factor (PDGF).
  • the isolated pMSCs were separately cultured in the above medium containing different human serum concentrations, wherein the final concentrations of human serum were 10 ml/L, 20 ml/L, 50 ml/L and 100 ml/L, and the final concentration was 20 ml/L.
  • the conventional medium of fetal bovine serum was used as a control, and the cells were cultured for 10 generations under the conventional culture conditions.
  • the pMSCs cultured in each experimental group and the control group were detected, and the differentiation ability and growth rate of the cells cultured in the experimental group were found.
  • the biological characteristics such as the phenotype are comparable to those of the control cultured cells, and are similar to those of the fetal bovine serum cultured mesenchymal stem cells reported in the related literature. (The results are not shown).
  • Table 1 Comparison of characteristics of human pMSCs at different serum concentrations (the higher the number + indicates the higher the index) The following results were obtained for human pMSCs cultured at a concentration of 20 ml/L human serum: 1. Morphological and immunophenotypic identification of human pMSCs And cell cycle assay
  • Human pMSCs were isolated as described above and placed in 20 ml/L fetal bovine serum medium, 20 ml/L human peripheral blood serum medium, and 20 ml/L human umbilical cord serum medium in three different cell culture systems. Subculture, cell culture until the third generation was observed under a microscope, the cells were fusiform, and the fish were arranged in a cluster. There was no difference in cell morphology under the three system cultures. And after passing the 7th generation, the shape remains unchanged. ( Figure 5)
  • the spindle cell phenotype obtained after culture was detected by direct immunofluorescence.
  • the cells were labeled with anti-human CD29, CD44, CD105, Flk-1, CD31 labeled with fluorescein isothiocyanate (FITC) or phycoerythrin (PE).
  • FITC fluorescein isothiocyanate
  • PE phycoerythrin
  • the CD34, CD45, and HLA-DR antibodies (all of which were purchased from BD) were labeled and subjected to flow cytometry.
  • the flow cytometer was BD FACScan (Becton Dickinson).
  • the phenotypic test results showed that there was no significant difference between 20 ml/L fetal bovine serum medium, 20 ml/L peripheral blood serum medium and pMSCs cultured in 20 ml/L umbilical cord serum medium.
  • the phenotypic identification of the spindle cells obtained from the third generation was performed.
  • the positive rates of CD29, CD44, CD105, MHC-1 and Flk-1 were over 95%, CD31, CD33, CD34, CD45, CD117 and MHC II.
  • the positive rate of the class of molecules is below 5%.
  • the cell cycle was measured by flow cytometry.
  • the cells were fixed with 80% cold ethanol at 4 ° C for 1 h, washed twice with PBS, resuspended in 0.5 ml PBS, added with RnaseA (100 g/ml), and incubated at 37 °C for 30 minutes. Stained with propidium iodide (Sigma, 5 ⁇ g/ml) before the measurement.
  • Cell cycle was analyzed with ModiFit software (Becton Dickinson). Cell cycle assays were performed at passages 3 and 7 respectively.
  • the pMSCs cultured in the third and seventh generations were cultured in three mediums, and induced to differentiate into osteoblasts, fat and endothelium by conventional methods.
  • the differentiation ability of pMSCs in peripheral blood serum and cord blood serum was found. There was no significant difference in the differentiation ability of pMSCs with fetal bovine serum system. (Fig. 8-1, Fig. 8-2, Fig. 8-3)
  • the 3rd and 7th generation pMSCs were cultured in three mediums, and the cells were seeded in a 24-well plate at 5 ⁇ 10 3 cells/well, then 3 wells were digested every 24 hours, and the cells were collected and used. 0.4% of the trypan blue counted live cells and then plotted the growth curve.
  • the results showed that pMSCs cultured in peripheral blood serum medium proliferated faster, the doubling time was about 28.5 hours; the doubling time of pMSCs cultured in fetal bovine serum medium was about 29.4 hours, and the doubling time of pMSCs in umbilical cord serum medium was about 30. Hours, the differences between the three were not statistically significant.
  • FIG. 9 Example 4: Application of human pMSCs to inhibit tumor cell proliferation
  • the human pMSCs prepared by the method described in the present application specifically expressed Nanog and Dkk-1 genes, and were detected by RT-PCR, and the results showed that the Nanog and Dkk-1 genes were positive (Fig. 10).
  • 3 H-thymidine 3 H-thymidine, 3 H -TDR incorporation assay tumor cell proliferation.
  • the 30 Gy-irradiated pMSCs were co-cultured with cells of three human hematological tumor cell lines (K562, HL60, MCF7) at a ratio of 1:10. The results showed that: After co-culture with pMSCs, the proliferation ability of the three tumor cells was compared with that of the culture alone. The decrease was observed in which K562 decreased by 77%, HL60 decreased by 80%, and MCF7 decreased by 56%. The difference was statistically significant (t test, p ⁇ 0.05) (Fig. 11-1).
  • the cell cycle of k562 was detected by flow cytometry.
  • the pMSCs irradiated with 30 Gy were co-cultured with k562 at a ratio of 1:10.
  • the results showed that the proportion of cells in the G0/G1 phase (62.07 ⁇ 5.8% vs. 45.23 ⁇ 6.9) was compared between the cocultured K562 (Fig. 11-2, group 2) and the culture alone (Fig. 11-2, group 1). %, p ⁇ 0.05) increased significantly.
  • the transwell assay was used to detect the effect of soluble factors, and the neutralizing antibody assay was used to determine the soluble factor class.
  • the results showed that after transwell, the proportion of cells in the G0/G1 phase (63.65 8.43%) was compared between the co-cultured K562 (Fig. 11-2, group 4) and the culture alone (Fig. 11-2, group 1). There was a significant increase in 45.23 ⁇ 6.9%, p ⁇ 0.05). However, there was no statistical difference in k562 cell cycle between transwell and untranswelled co-culture (t test, p>0.05).
  • the method of transfection with siRNA-retroviral vector specifically targets RNA interference of Nanog and DKK-1 genes of pMSCs.
  • the expression of the target gene in the cells after transfection of the interference vector was detected by Real-time RT-PCR and western blot.
  • the pMSCs (SiN group) in which the Nanog gene was interfered and the pMSCs (SiD group) in which the DKK-1 gene was interfered were co-cultured with k562 at a ratio of 1:10 after 30 Gy irradiation; the control group was a negative control for transfection.
  • the interfering empty vector pMSCs (SiM group) were co-cultured with k562 at a ratio of 1:10 after 30 Gy irradiation.
  • Nanog gene was down-regulated in pMSCs that interfered with Nanog gene
  • DKK-1 gene was also down-regulated (Fig. 11-3B, C).
  • the transcriptional regulation of genes which in turn affects the expression of their proteins.
  • the cell cycle of k562 was detected by flow cytometry.
  • the results showed that the proportion of k562 cells in the G0/G1 phase (52.09 ⁇ 3.36 vs. 62.02 ⁇ 4.36, p ⁇ 0.05) was reduced in the SiD group compared with the SiM group.
  • the SiN group was in the G0/G1 phase at the K562 compared with the SiM group.
  • the proportion of cells 46.32 ⁇ 4.77 vs. 62.02 ⁇ 4.36, p ⁇ 0.05
  • was significantly reduced (Fig. 11-4).
  • the activation of Wnt signaling pathway allows ⁇ -catenin to accumulate in cells, and the accumulation of ⁇ -catenin into the nucleus promotes the rapid entry of cells from the G1 phase into the S phase, thereby promoting tumor cell proliferation.
  • the accumulation of ⁇ -catenin protein in k562 cells was detected by westrn blot.
  • the pMSCs interfered with by the Nanog gene and the pMSCs interfered with the DKK-1 gene were co-cultured with k562 at a ratio of 1:10 after 30 Gy irradiation; the control group was a pMSCs transfected with a negative control interference vector. After 30 Gy irradiation, co-culture with k562 and normal k562 cultured alone were performed at a ratio of 1:10.
  • the expression of the inhibitory genes P21 and p27 was decreased in the SiN group and the SiD group compared with the SiM group.
  • Fig. 11-6A, B the expression of the regulatory gene c-myc, CyclinD2 was increased (Fig. 11-6C, D), indicating that pMSCs inhibit the proliferation of k562 cells by expressing Nanog, Dkk gene.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé permettant la préparation in vitro de cellules souches mésenchymateuse primaires adultes humaines (pMSC, positives aux marqueurs Flk1 et Nanog) dérivées de tissus adultes humains (moelle) à grande échelle et les produits obtenus à l'aide de ce procédé. L'invention porte aussi sur l'utilisation de ce procédé et les produits obtenus, à l'aide de ce dernier, par inhibition de la prolifération de cellules tumorales. Il est possible de réaliser l'objectif de préparation de pMSC à grande échelle grâce à la modification des procédés et des paramètres clés de la préparation de pMSC, par exemple en simplifiant le procédé de triage magnétique des cellules, en utilisant un milieu de culture à base de sérum humain et non un milieu de culture à base de sérum bovin, et en utilisant des conditions de culture présentant une faible teneur en oxygène (2 %). Ainsi, l'utilisation des propriétés permettant d'exprimer le gène Nanog des pMSC a permis d'aboutir à une nouvelle utilisation des pMSC pour inhiber la prolifération de cellules tumorales.
PCT/CN2007/070637 2007-09-05 2007-09-05 Milieu de culture et procédé destinés à une culture in vitro de cellules souches mésenchymateuses primaires adultes humaines à grande échelle, cellules souches mésenchymateuses primaires obtenues à l'aide de ce procédé, utilisations correspondantes Ceased WO2009030092A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN2007801003999A CN101821383B (zh) 2007-09-05 2007-09-05 一种用于人成体原始间充质干细胞体外规模化培养的培养基、方法及获得的原始间充质干细胞及其应用
PCT/CN2007/070637 WO2009030092A1 (fr) 2007-09-05 2007-09-05 Milieu de culture et procédé destinés à une culture in vitro de cellules souches mésenchymateuses primaires adultes humaines à grande échelle, cellules souches mésenchymateuses primaires obtenues à l'aide de ce procédé, utilisations correspondantes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/070637 WO2009030092A1 (fr) 2007-09-05 2007-09-05 Milieu de culture et procédé destinés à une culture in vitro de cellules souches mésenchymateuses primaires adultes humaines à grande échelle, cellules souches mésenchymateuses primaires obtenues à l'aide de ce procédé, utilisations correspondantes

Publications (2)

Publication Number Publication Date
WO2009030092A1 true WO2009030092A1 (fr) 2009-03-12
WO2009030092A9 WO2009030092A9 (fr) 2010-04-22

Family

ID=40428443

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/070637 Ceased WO2009030092A1 (fr) 2007-09-05 2007-09-05 Milieu de culture et procédé destinés à une culture in vitro de cellules souches mésenchymateuses primaires adultes humaines à grande échelle, cellules souches mésenchymateuses primaires obtenues à l'aide de ce procédé, utilisations correspondantes

Country Status (2)

Country Link
CN (1) CN101821383B (fr)
WO (1) WO2009030092A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101760445A (zh) * 2010-02-11 2010-06-30 中国人民解放军总医院 自体骨髓间充质干细胞的扩增方法
CN102188446A (zh) * 2010-03-11 2011-09-21 中国医学科学院肿瘤研究所 人成体干细胞在治疗恶性实体瘤中的用途
CN103352027A (zh) * 2013-05-07 2013-10-16 中国人民解放军第二军医大学 肿瘤干细胞的悬浮培养方法
CN106039314A (zh) * 2016-05-30 2016-10-26 深圳爱生再生医学科技有限公司 抑制肿瘤细胞增殖的干细胞制剂及其制备方法和应用
CN106701669A (zh) * 2015-07-29 2017-05-24 华南生物医药研究院 临床治疗用间充质干细胞及其制备方法和用途
CN108220229A (zh) * 2017-12-18 2018-06-29 北京康亿瑞生物科技有限公司 一种提高脐带来源间充质干细胞原代细胞产量的制备方法
WO2020253763A1 (fr) * 2019-06-18 2020-12-24 中国医学科学院基础医学研究所 Population de cellules souches hétérogènes, son procédé de préparation et son utilisation
CN114317409A (zh) * 2014-12-31 2022-04-12 迈克尔·莫勒 用于人脂肪基质细胞临床生长的细胞培养基的人血清

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012075636A1 (fr) * 2010-12-09 2012-06-14 中国医学科学院基础医学研究所 Marqueurs de modification épigénétique permettant de prédire le potentiel de différenciation de cellules souches
CN110894493A (zh) * 2019-10-28 2020-03-20 吉林大学 一种重编程间充质干细胞及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027996A1 (fr) * 1998-11-09 2000-05-18 Consorzio Per La Gestione Del Centro Di Biotecnologie Avanzate Milieu exempt de serum pour cellules de type chondrocyte
CN1434119A (zh) * 2001-09-19 2003-08-06 中国医学科学院中国协和医科大学血液学研究所 间充质干细胞表型的成体干细胞重建造血方法的建立及应用
US20030232432A1 (en) * 2002-04-09 2003-12-18 Reliance Life Sciences Pvt. Ltd. Growth of human Mesenchymal Stem Cells (hMSC) using umbilical cord blood serum and the method for the peparation thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027996A1 (fr) * 1998-11-09 2000-05-18 Consorzio Per La Gestione Del Centro Di Biotecnologie Avanzate Milieu exempt de serum pour cellules de type chondrocyte
CN1434119A (zh) * 2001-09-19 2003-08-06 中国医学科学院中国协和医科大学血液学研究所 间充质干细胞表型的成体干细胞重建造血方法的建立及应用
US20030232432A1 (en) * 2002-04-09 2003-12-18 Reliance Life Sciences Pvt. Ltd. Growth of human Mesenchymal Stem Cells (hMSC) using umbilical cord blood serum and the method for the peparation thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
L I HAI SHENG ET AL.: "Continous hypoxia improves the proliferation of human bone marrow-derived mesenchymal stem cells in vitro", BASIC &CLINICAL MEDICINE, vol. 25, no. 3, 31 March 2005 (2005-03-31) *
VENKATA LOKESH BATTULA ET AL.: "Human placenta and bone marrow derived MSC cultured in serum-free,b-FGF-containing medium express cell surface frizzled-9 and SSEA-4 and give rise to multilineage differentiation", DIFFERENTIATION, vol. 75, 2007, pages 279 - 291, XP026765256 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101760445A (zh) * 2010-02-11 2010-06-30 中国人民解放军总医院 自体骨髓间充质干细胞的扩增方法
CN101760445B (zh) * 2010-02-11 2013-07-10 中国人民解放军总医院 自体骨髓间充质干细胞的扩增方法
CN102188446A (zh) * 2010-03-11 2011-09-21 中国医学科学院肿瘤研究所 人成体干细胞在治疗恶性实体瘤中的用途
CN103352027A (zh) * 2013-05-07 2013-10-16 中国人民解放军第二军医大学 肿瘤干细胞的悬浮培养方法
CN114317409A (zh) * 2014-12-31 2022-04-12 迈克尔·莫勒 用于人脂肪基质细胞临床生长的细胞培养基的人血清
CN106701669A (zh) * 2015-07-29 2017-05-24 华南生物医药研究院 临床治疗用间充质干细胞及其制备方法和用途
CN106039314A (zh) * 2016-05-30 2016-10-26 深圳爱生再生医学科技有限公司 抑制肿瘤细胞增殖的干细胞制剂及其制备方法和应用
CN108220229A (zh) * 2017-12-18 2018-06-29 北京康亿瑞生物科技有限公司 一种提高脐带来源间充质干细胞原代细胞产量的制备方法
CN108220229B (zh) * 2017-12-18 2021-05-04 北京康亿瑞生物科技有限公司 一种提高脐带来源间充质干细胞原代细胞产量的制备方法
WO2020253763A1 (fr) * 2019-06-18 2020-12-24 中国医学科学院基础医学研究所 Population de cellules souches hétérogènes, son procédé de préparation et son utilisation

Also Published As

Publication number Publication date
WO2009030092A9 (fr) 2010-04-22
CN101821383B (zh) 2013-12-18
CN101821383A (zh) 2010-09-01

Similar Documents

Publication Publication Date Title
WO2009030092A1 (fr) Milieu de culture et procédé destinés à une culture in vitro de cellules souches mésenchymateuses primaires adultes humaines à grande échelle, cellules souches mésenchymateuses primaires obtenues à l'aide de ce procédé, utilisations correspondantes
US20250049847A1 (en) A method for inducing ipsc differentiation to obtain cd34+cells and nk cells and application thereof
KR20150126943A (ko) 규정된 조건하에서 인간 만능성 줄기 세포의 조혈내피세포 분화를 위한 방법 및 재료
KR20120008223A (ko) 양막유래 중간엽 줄기세포 배양을 위한 배지조성물 및 이를 이용한 양막유래 중간엽 줄기세포의 배양방법
CN102329769A (zh) 一种获得造血干细胞的方法
CN102978156A (zh) 一种骨髓间充质干细胞的体外扩增纯化培养方法及培养基
CN101818127A (zh) 一种小鼠精原干细胞分离培养方法
CN102344906A (zh) 一种毛囊干细胞的分离培养方法
CN111826348A (zh) 一种人诱导性多能干细胞来源的间充质干细胞体外高效制备方法和应用
CN104342402A (zh) 一种骨髓去分化间充质干细胞的培养方法
CN102206610B (zh) 造血祖细胞的制备方法及其专用培养基
CN110872574B (zh) 一种高效可靠的hESC-MSC制备方法
KR101896803B1 (ko) 인간 만능줄기세포로부터 중간엽 줄기세포로의 분화 유도 생산율을 증가시키는 방법 및 이에 의해 생성된 중간엽 줄기세포
KR20120006386A (ko) 1기 태반조직 유래 줄기세포 및 이를 함유하는 세포치료제
CN110592007B (zh) 一种间充质干细胞及其制备方法和应用
CN104745529B (zh) 瘦素在诱导胚胎干细胞分化为造血干/祖细胞中的用途及其应用
WO2019033482A1 (fr) Procédé de différenciation directionnelle de cellules souches pluripotentes humaines
CN107674858B (zh) 骨髓内皮祖细胞的分离培养基和分离方法
CN112852709B (zh) 小鼠肺类器官培养方法
KR102142254B1 (ko) 3,4''-다이하이드록시플라본을 이용한 소변줄기세포의 분리 효율 향상 및 소변줄기세포유래 만능줄기세포의 조혈줄기세포 분화 효율을 촉진시키는 방법
CN110846277A (zh) 一种永生化的小鼠小胶质细胞系B6Mi1及其建立方法和应用
CN102533641B (zh) 体外无血清成体干细胞放大培养的方法及其培养液
WO2023143006A1 (fr) Kit pour induire des cellules ips dans des cellules nk et son procédé d'utilisation
WO2013123607A1 (fr) Procédé de culture in vitro sans sérum et milieu de culture pour cellules souches adultes
CN107460169A (zh) 维生素c在制备培养基中的用途

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780100399.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07801046

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07801046

Country of ref document: EP

Kind code of ref document: A1